Crizotinib (PF-02341066)

Licensed by Pfizer Catalog No.S1068

Crizotinib (PF-02341066) Chemical Structure

Molecular Weight(MW): 450.34

Crizotinib (PF-02341066) is a potent inhibitor of c-Met and ALK with IC50 of 11 nM and 24 nM in cell-based assays, respectively.

Size Price Stock Quantity  
In DMSO USD 220 In stock
USD 110 In stock
USD 170 In stock
USD 570 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 71 Publications

12 Customer Reviews

  • (c) Western blot analyses of p-Akt (Ser473) and p-S6RP (Ser235 and Ser236) in two RCT-E565 transplanted tumors treated with vehicle or PF02341066. Samples were isolated 4 h after the last dose from mice treated with PF02341066 for 3 d. (d) Responses of RCT-E565 transplanted tumors in athymic mice to PF02341066 or vehicle. Data are means ±s.e.m. (each group, n = 6). *P < 0.005, **P < 0.001 (Student,s t test).

    Nat Med 2011 17, 1116-1120. Crizotinib (PF-02341066) purchased from Selleck.

    Ba/F3 cells grown in the presence of IL-3, or Ba/F3 cells expressing native EML4-ALK (clone #2, #10, #101, and #155) and EML4-ALK L1196M (clone #216, #302, #303, and #355), were treated with CH5424802 or PF-02341066 for 48 hr, and then the viable cells were measured by the Cell Titer-Glo Luminescent Cell Viability Assay. IC50 values were determined by plotting the drug concentration versus percentage of cell growth inhibition. Data are shown as mean ±SD (n = 3).

     

     

    Cancer Cell 2011 19, 679–690. Crizotinib (PF-02341066) purchased from Selleck.

  • Mice bearing Ba/F3-EML4-ALK (clone #10) and EML4-ALK L1196M (clone #303) were administered vehicle, CH5424802 (60 mg/kg), or PF-02341066 (100 mg/kg) orally once daily for 8 days. Tumor volume for each dose group was measured. Data are shown as mean ± SD (n = 5). Parametric Dunnett’s test: ***p < 0.001; N.S., not significant, versus vehicle treatment at final day. For pharmacodynamic assay, mice bearing Ba/F3-EML4-ALK (clone #10) and -EML4-ALK L1196M (clone #303) were orally administered at single dose of vehicle, CH5424802 (60 mg/kg), or PF-02341066 (100 mg/kg), and the tumors were collected and lysed at 4 hr post-dosing. STAT3 and phosphorylated STAT3 (Tyr 705) were detected by immunoblot analysis using antibodies against each of them (n = 2 per group).

     

     

    Cancer Cell 2011 19, 679–690. Crizotinib (PF-02341066) purchased from Selleck.

    (A) Immunoblots of MPM cells treated with the indicated concentrations of crizotinib alone for 24 h with HGF stimulation.

    Sci Rep, 2016, 6:32992. Crizotinib (PF-02341066) purchased from Selleck.

  • Viability of Ba/F3 cells stably expressing DCTN1-ALK or EML4-ALK cDNAs after treatment with crizotinib (C). Ba/F3 cells transduced with lentiviral cDNA or empty vector were subjected to the assay, and the number of cells was counted at 72 hours.

    Oncologist, 2017, 22(2):158-164. Crizotinib (PF-02341066) purchased from Selleck.

    Combination of EGCG with c-MET inhibitor has enhanced inhibitory effects on the growth of OS cells. MG-63 and U-2OS cells were treated with crizotinib (0.05 mM) and/or EGCG (0.08 g/L) for 48 h, and the effects on cell apoptosis (b) were determined using flow cytometry. *P<0.05 versus the control; #P<0.05 versus crizotinib-treated groups or EGCG-treated groups

    Tumour Biol, 2016, 37(4):4373-82. Crizotinib (PF-02341066) purchased from Selleck.

  • (A) VimPro-Fluc activity in spheroids after 72-h treatment with control modulators of epithelial-mesenchymal transition (EMT) normalized to spheroid viability and compared to vimentin protein expression using Western blot analysis. (B) Dose-response curves for both U0126 and axitinib control modulators of EMT. RLU, relative luminescence units.

    J Biomol Screen 2011 16, 141-154. Crizotinib (PF-02341066) purchased from Selleck.

    Secondary assay development. The invasive potential of MDA-MB-231 spheroids was measured using modified Boyden chambers coated with Matrigel™. Invading cells were fixed, stained with DAPI, and quantified by fluorescence microscopy using 5 random fields per filter insert in triplicate. U0126, PF2341066, axitinib, and PKC412 inhibited the invasive potential of MDA-MB-231 spheroids by ~90% as compared to untreated spheroids (UT). ***p ≤ 0.001. IGF1R and dasatinib displayed no statistical difference as compared to UT MDA-MB-231 spheroids.

    J Biomol Screen 2011 16, 141-154. Crizotinib (PF-02341066) purchased from Selleck.

  • Crizotinib impaired tumor vascularization. a-e Representative photomicrographs (40×) of CD31 staining in negative control and indicated LFD, HFD, vehicle (veh) and crizotinib (criz) treated groups. b CD31 was quantified on 5–6 randomly selected regions of n = 2 sections each from each mouse. N = 9–10 mice (a vs b, Veh vs Criz, P = 0.0138)

    Springerplus, 2016, 5:348. Crizotinib (PF-02341066) purchased from Selleck.

    Inhibition of signaling pathway activation in lung tumor cell lines by kinase inhibitors. Lung tumor cells were cultured in 10% FBS until reaching ∼80% confluence and then the cells were starved in serum-free medium for overnight, followed by 4-hour treatment with the inhibitors. Cell lysates were then prepared and used for determination of the pathway activation signals by the CEER assay.

    Int J Proteomics 2011 2011, 215496. Crizotinib (PF-02341066) purchased from Selleck.

  • Inhibition of anchorage-independent growth of lung tumor cell lines by selected inhibitors. Each selected cell line was treated with the indicated inhibitor at 0.1 μM and 1 μM concentrations for two weeks and cell colony size formation was scored under the Nikon inverted-phase microscope.

    Int J Proteomics 2011 2011, Article ID 215496. Crizotinib (PF-02341066) purchased from Selleck.

    Western blot analysis of c-Met, MAPK and Akt. 0-100nM PF2341066 was added.

     

     

    Dr. Zhang of Tianjin Medical University. Crizotinib (PF-02341066) purchased from Selleck.

Purity & Quality Control

Choose Selective c-Met Inhibitors

Biological Activity

Description Crizotinib (PF-02341066) is a potent inhibitor of c-Met and ALK with IC50 of 11 nM and 24 nM in cell-based assays, respectively.
Targets
c-Met [1]
(A549, MDA-MB-231, GTL-16, HT29, 786-O, Colo-205, A498 cells)
ALK [1]
(Karpas299 cells)
11 nM 24 nM
In vitro

PF-2341066 displays similar potency against c-Met phosphorylation in mIMCD3 mouse or MDCK canine epithelial cells with IC50 of 5 nM and 20 nM, respectivly. PF-2341066 shows improved or similar activity against NIH3T3 cells engineered to express c-Met ATP-binding site mutants V1092I or H1094R or the P-loop mutant M1250T with IC50 of 19 nM, 2 nM and 15 nM, respectively, compared with NIH3T3 cells expressing wild-type receptor with IC50 of 13 nM. In contrast, a marked shift in potency of PF-2341066 is observed against cells engineered to express c-Met activation loop mutants Y1230C and Y1235D with IC50 of 127 nM and 92 nM, respectively, compared with wild-type receptor. PF-2341066 also potently prevents the phosphorylation of c-Met in NCI-H69 and HOP92 cells, with IC50 of 13 nM and 16 nM, respectively, which express the endogenous c-Met variants R988C and T1010I, respectively. PF-2341066 is >1,000-fold selective for the VEGFR2 and PDGFRβ RTKs, >250-fold selective for IRK and Lck, and ∼40- to 60-fold selective for Tie2, TrkA, and TrkB, all compared with c-Met. PF-2341066 is 20- to 30-fold selective for RON and Axl RTKs. In contrast, PF-2341066 shows a near-equivalent IC50 of 24 nM against the nucleophosmin (NPM)-anaplastic lymphoma kinase (ALK) oncogenic fusion variant of the ALK RTK expressed by the KARPAS299 human anaplastic large cell lymphoma (ALCL) cell line. PF-2341066 inhibits c-Met–dependent neoplastic phenotypes of cancer cells and angiogenic phenotypes of endothelial cells. PF-2341066 suppresses human GTL-16 gastric carcinoma cell growth with IC50 of 9.7 nM. PF-2341066 induces apoptosis in GTL-16 cells with IC50 of 8.4 nM. PF-2341066 inhibits HGF-stimulated human NCI-H441 lung carcinoma cell migration and invasion with IC50 of 11 nM and 6.1 nM, respectively. PF-2341066 inhibits MDCK cell scattering with IC50 of 16 nM. PF-2341066 prevents HGF-stimulated c-Met phosphorylation, cell survival, and Matrigel invasion with IC50 of 11 nM, 14 nM and 35 nM, respectively. In addition, PF-2341066 prevents serum-stimulated HMVEC branching tubulogenesis (formation of vascular tubes) in fibrin gels. [1] PF-2341066 also potently inhibits NPM-ALK phosphorylation in Karpas299 or SU-DHL-1 ALCL cells with an IC50 of 24 nM. PF-2341066 potently prevents cell proliferation, which is associated with G(1)-S-phase cell cycle arrest and induction of apoptosis in ALK-positive ALCL cells with IC50 of 30 nM, but not ALK-negative lymphoma cells. [2] Besides, PF-2341066 prevents osteosarcoma behavior associated with primary tumor growth (i.e., proliferation and survival) as well as metastasis (eg, invasion and clonogenicity). [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
BAF3 MUTDfZRwfG:6aXOgRZN{[Xl? MnLyOFghcA>? NIHxZ|NFVVOR MmfnR5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmFHOyClZXzsd{BmgHC{ZYPzbY5oKEGOSzDGNVE4PExibYX0ZY51KGOxZYjwdoV{e2mwZzDFUWw1KHerdHigTWM2OCCxZjCwMlYzKM7:TR?= MXOyNVU4OjV6OR?=
BAF3 MnXFR5l1d3SxeHnjJGF{e2G7 MXm0PEBp NFjQXohFVVOR M4\zSGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCTjNiY3XscJMh\XiycnXzd4lv\yCDTFugUFEyQT[PIH31eIFvfCClb3X4dJJme3OrbnegSW1NPCC5aYToJGlEPTBib3[gNk4zKM7:TR?= NGXXSnQzOTV5MkW4PS=>
BAF3 NWX4R3JoS3m2b4TvfIlkKEG|c3H5 MYC0PEBp MofRSG1UVw>? NHzQcFREgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBDSUZ|IHPlcIx{KGW6cILld5NqdmdiRV3MOE1CVEtid3n0bEBKSzVyIH;mJFAvOjhizszN NXfPXnBnOjF3N{K1PFk>
Kelly NUH0XYtlS3m2b4TvfIlkKEG|c3H5 MYXEUXNQ M2PYRWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGtmdGy7IHPlcIx{KGW6cILld5NqdmdiQVzLJGYyOTd2TDDteZRidnRid3n0bEBKSzVyIH;mJFAvPDJizszN MU[yNVU4OjV6OR?=
SH-SY5Y MmS1R5l1d3SxeHnjJGF{e2G7 M2XqTmROW09? NUXaSGZ7S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hW0hvU2m1XUBk\WyuczDlfJBz\XO|aX7nJGFNUyCIMUG3OGwhdXW2YX70JJdqfGhiSVO1NEBw\iByLkWzJO69VQ>? NEO5Z3ozOTV5MkW4PS=>
SMS-KCN NWfZXVN1S3m2b4TvfIlkKEG|c3H5 MULEUXNQ NFLR[otEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBUVVNvS1POJINmdGy|IHX4dJJme3OrbnegRWxMKFJzMke1VUBufXSjboSge4l1cCCLQ{WwJI9nKDBwOUGg{txO NXzHNmExOjF3N{K1PFk>
BAF3 MVvDfZRwfG:6aXOgRZN{[Xl? MUC0PEBp MWPEUXNQ NEDXTZJEgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBDSUZ|IHPlcIx{KGW6cILld5NqdmdiVHXsMWFNUyC5aYToJGlEPTBib3[gNE4yQSEQvF2= Mn3LNlE2PzJ3OEm=
3T3 M{O1dWZ2dmO2aX;uJGF{e2G7 M3nseVEhcA>? MoT3SG1UVw>? NVPvepVuUW6qaXLpeIlwdiCxZjDSU24h[XO|ZYPz[YQh[XNiZ4Lve5RpKG[jY4Tvdk1qdmS3Y3XkJIF2fG:yaH;zdIhwenmuYYTpc44hf2m2aDDJR|UxKG:oIECuNFgh|ryP MmS1NlE5OTJ2MUS=
3T3-E NX;ONmo4TnWwY4Tpc44hSXO|YYm= MkGwNUBp NEXRb3JFVVOR MofBTY5pcWKrdHnvckBw\iCWSVWyJIF{e2W|c3XkJIdzd3e2aDDmZYN1d3JvaX7keYNm\CCjdYTvdIhwe3Cqb4L5cIF1cW:wIIfpeIghUUN3MDDv[kAxNjR2ODFOwG0> MYqyNVgyOjRzNB?=
A549 NWXNWWlqU2mwYYPlJGF{e2G7 NX:zbGF{OSCq MV;EUXNQ MknHTY5pcWKrdHnvckBw\iCqdX3hckBz\WOxbXLpcoFvfCClLV3FWEBscW6jc3Wg[ZhxemW|c3XkJIF{e2W|c3XkJIF{KGmwaHnibZRqd25ib3[gTGdHNWmwZIXj[YQh[XW2b4Doc5NxcG:{eXzheIlwdiC5aYToJGlEPTBib3[gNE4xODhizszN NXnRZ5dROjF6MUK0NVQ>
BAF3-BCL MYDGeY5kfGmxbjDBd5NigQ>? MnjqNUBp NXzt[Wk2TE2VTx?= NYLjbXVpUW6qaXLpeIlwdiCxZjDBRmwh[XO|ZYPz[YQh[XNiZ4Lve5RpKG[jY4Tvdk1qdmS3Y3XkJIF2fG:yaH;zdIhwenmuYYTpc44hf2m2aDDJR|UxKG:oIEGuNVU6KM7:TR?= M37aSlIyQDF{NEG0
HEK293 MYPGeY5kfGmxbjDBd5NigQ>? M{LqRlEhcA>? MmjmSG1UVw>? NXHhXXh{UW6qaXLpeIlwdiCxZjDBXGwh[XO|ZYPz[YQh[XNiZ4Lve5RpKG[jY4Tvdk1qdmS3Y3XkJIF2fG:yaH;zdIhwenmuYYTpc44hf2m2aDDJR|UxKG:oIECuNlk1KM7:TR?= Ml\nNlE5OTJ2MUS=
HEK293 MUnGeY5kfGmxbjDBd5NigQ>? NGTndmEyKGh? NV7LZYNMTE2VTx?= M{TGTWlvcGmkaYTpc44hd2ZiSWKgZZN{\XO|ZXSgZZMh\3Kxd4ToJIZi[3Sxcj3pcoR2[2WmIHH1eI9xcG:|cHjvdplt[XSrb36ge4l1cCCLQ{WwJI9nKDJwOEi3JO69VQ>? NGC1cXkzOThzMkSxOC=>
Jurkat MWrGeY5kfGmxbjDBd5NigQ>? NWTjSoxROSCq NHPjUodFVVOR MXvJcohq[mm2aX;uJI9nKEyFSzDhd5Nme3OnZDDhd{Boem:5dHig[oFkfG:{LXnu[JVk\WRiYYX0c5Bpd3OyaH;yfYxifGmxbjD3bZRpKEmFNUCgc4YhOi55NEGg{txO NXvDeYttOjF6MUK0NVQ>
KARPAS299 Mn;6T4lv[XOnIFHzd4F6 M4DQb|EhcA>? M3LVcWROW09? MlrnTY5pcWKrdHnvckBw\iCDTFugZZN{\XO|ZXSgZZMh\3Kxd4ToJIZi[3Sxcj3pcoR2[2WmIHH1eI9xcG:|cHjvdplt[XSrb36ge4l1cCCLQ{WwJI9nKDBwMEKg{txO NVfJc5VIOjF6MUK0NVQ>
PAE MWPGeY5kfGmxbjDBd5NigQ>? M1;rVVEhcA>? MVnEUXNQ MmfpTY5pcWKrdHnvckBw\iCWUlvCJIF{e2W|c3XkJIF{KGe{b4f0bEBn[WO2b4KtbY5lfWOnZDDheZRweGixc4Doc5J6dGG2aX;uJJdqfGhiSVO1NEBw\iByLkO5PUDPxE1? NEiwdmgzOThzMkSxOC=>
BAF3 MkL4SpVv[3Srb36gRZN{[Xl? M3LmflIuOyCm MkH2SG1UVw>? M1PtOGlvcGmkaYTpc44hd2ZiVFXMMYZ2e2WmIHnud5VtcW5icnXj[ZB1d3JiZYjwdoV{e2WmIIfpeIghUUN3MDDv[kAyNjZ2MzFOwG0> NV6zSGF[OjN5NEKyOVI>
KARPAS299 M2PqWmN6fG:2b4jpZ{BCe3OjeR?= NWLnd2R1Oi1|IHS= MYXEUXNQ M1rK[2lEPTB;MD6wOlQzKM7:TR?= M3nHVlI{PzR{MkWy
EBC1 MlTtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1\WZVczKGh? MVjEUXNQ MVzJR|UxRTBwMEKzJO69VQ>? MXWyN|k6OzN{OB?=
HCT116 Mo\BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mmn5O|IhcA>? NVLRfpdOTE2VTx?= MmXGTWM2OD1zND64NkDPxE1? NF\BN5UzOzl7M{OyPC=>
MCF7 MknRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHLIe|U4OiCq NYm4TpF1TE2VTx?= Mkm3TWM2OD17LkW4JO69VQ>? MkHqNlM6QTN|Mki=
MDA-MB-231 MkfZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{jCZlczKGh? MoTkSG1UVw>? MYPJR|UxRTFyLkig{txO NEGyT5YzOzl7M{OyPC=>
MKN45 MoXGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3TiflczKGh? Mmf1SG1UVw>? MlXNTWM2OD1yLkCxN{DPxE1? NELNVVUzOzl7M{OyPC=>
NCI-H441 Mor6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXW3NkBp MojKSG1UVw>? MlPXTWM2OD1zNz6yOUDPxE1? M4Xxd|I{QTl|M{K4
NCI-H661 NF\zeopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlfUO|IhcA>? MXfEUXNQ NUDqOXd3UUN3ME2xNU41PyEQvF2= NEn0S4szOzl7M{OyPC=>
SK-MEL-28 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVvMfnZoPzJiaB?= MVHEUXNQ MnzlTWM2OD1zMD65O{DPxE1? M4Hy[FI{QTl|M{K4
SKOV3 NVfOW4t5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW\weJJ3PzJiaB?= MoS4SG1UVw>? M2T4ZWlEPTB;MUKuPFUh|ryP M4j0XFI{QTl|M{K4
SNU5 MnW1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmO4O|IhcA>? MlHCSG1UVw>? MX\JR|UxRTBwMEG2JO69VQ>? NWmzdWRHOjN7OUOzNlg>
NCI-H2228 MojuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml;KO|IhcA>? M{i3dGROW09? MVvJcohq[mm2aX;uJI9nKEGOSz3meZNqd25iZILpeoVvKGOnbHygdJJwdGmoZYLheIlwdiC5aYToJGlEPTBib3[gNE4yOThizszN NE\iNIQzPDR|MkmwPS=>
NCI-H3122 MlziS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIXlbIM4OiCq MUnEUXNQ NEHsdY5KdmirYnn0bY9vKG:oIFHMT{1nfXOrb36g[JJqfmWwIHPlcIwheHKxbHnm[ZJifGmxbjD3bZRpKEmFNUCgc4YhOC5zMEig{txO MUiyOFQ{OjlyOR?=
NCI-H3122 M4KwOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVX5V2VuPzJiaB?= MlnJSG1UVw>? MVPJcohq[mm2aX;uJI9nKEGOSz3meZNqd25iZILpeoVvKGOnbHygdJJwdGmoZYLheIlwdiCrbjDoeY1idiCQQ1mtTFMyOjJiY3XscJMhcGG{Yn;ybY5oKEGOSzDHNVI3QUFibYX0ZY51KHerdHigTWM2OCCxZjCwMlYzOyEQvF2= NHjmWnAzPDR|MkmwPS=>
NCI-H3122 M17r[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn3BO|IhcA>? MUjEUXNQ MWLJcohq[mm2aX;uJI9nKEGOSz3meZNqd25iZILpeoVvKGOnbHygdJJwdGmoZYLheIlwdiCrbjDoeY1idiCQQ1mtTFMyOjJiY3XscJMhcGG{Yn;ybY5oKEGOSzDMNVE6Pk1ibYX0ZY51KHerdHigTWM2OCCxZjCwMlg{QCEQvF2= MoDRNlQ1OzJ7MEm=
NIH-3T3 MXHLbY5ie2ViQYPzZZk> M{WwVFEhcA>? MVHEUXNQ MVjJcohq[mm2aX;uJI9nKGi3bXHuJJdqdGRidInw[UBGVUx2LX\1d4VlKEGOSzDlfJBz\XO|ZXSgZZN{\XO|ZXSgZZMheGixc4Doc5J6dGG2ZXSgRWxMKGyndnXsJJdqfGhiSVO1NEBw\iByLkC4JO69VQ>? MWqyOFQ{OjlyOR?=
NIH-3T3 NWKxU4tTU2mwYYPlJGF{e2G7 NXn6N2oxOSCq NHjK[VBFVVOR M{DnWGlvcGmkaYTpc44hd2ZiaIXtZY4hTU2OND3meZNm\CCDTFugS|EzPjmDIH31eIFvfCCneIDy[ZN{\WRiYYPz[ZN{\WRiYYOgdIhwe3Cqbz3BUGshdGW4ZXyge4l1cCCLQ{WwJI9nKDBwNkC1JO69VQ>? MYSyOFQ{OjlyOR?=
NIH-3T3 MVHLbY5ie2ViQYPzZZk> MWWxJIg> NV;QfVlmTE2VTx?= MmLQTY5pcWKrdHnvckBw\iCqdX3hckBGVUx2LX\1d4VlKEGOSzDTNVIxPllibYX0ZY51KGW6cILld5Nm\CCjc4Pld5Nm\CCjczDwbI9{eGixLVHMT{Bt\X[nbDD3bZRpKEmFNUCgc4YhOC54Mk[g{txO NHPacHkzPDR|MkmwPS=>
NIH-3T3 M2TOT2tqdmG|ZTDBd5NigQ>? M{\SWlEhcA>? MkXoSG1UVw>? NEPjcmhKdmirYnn0bY9vKG:oIHj1cYFvKEWPTESt[pV{\WRiQVzLJGwyOTl4TTDteZRidnRiZYjwdoV{e2WmIHHzd4V{e2WmIHHzJJBpd3OyaH:tRWxMKGyndnXsJJdqfGhiSVO1NEBw\iByLki0N{DPxE1? M16wOVI1PDN{OUC5
NIH-3T3 NXvabos3U2mwYYPlJGF{e2G7 MVKxJIg> MkDaSG1UVw>? M2fEXWlvcGmkaYTpc44hd2ZiaIXtZY4hTU2OND3meZNm\CCDTFugUFEyPTKUIH31eIFvfCCneIDy[ZN{\WRiYYPz[ZN{\WRiYYOgdIhwe3Cqbz3BUGshdGW4ZXyge4l1cCCLQ{WwJI9nKDFwMEK2JO69VQ>? M2HvdFI1PDN{OUC5
BAF3 MkD1SpVv[3Srb36gRZN{[Xl? MY[3NkBp MYrEUXNQ MoHYTY5pcWKrdHnvckBw\iCQUF2vRWxMKHS{YX7z[oVkfGWmIHHzd4V{e2WmIHHzJINmdGxiZ4Lve5RpKGmwaHnibZRqd25id3n0bEBKSzVyIH;mJFAvODVzIN88US=> Mk[zNlQ1Pjh4M{K=
BAF3 MmOyR5l1d3SxeHnjJGF{e2G7 MVq3NkBp MUjEUXNQ NVK4VmhkUUN3ME2wMlk5KM7:TR?= MlTVNlQ1Pjh4M{K=
NIH-3T3 MkTKT4lv[XOnIFHzd4F6 MWixJIg> MWrJcohq[mm2aX;uJI9nKGi3bXHuJGVOVDRvZoXz[YQhSUyNIF[xNVc1VCCvdYThcpQh\XiycnXzd4VlKGG|c3Xzd4VlKGG|IIDoc5NxcG9vQVzLJIxmfmWuIIfpeIghUUN3MDDv[kAxNjF4NTFOwG0> MWKyOFgyQTFzNh?=
NIH-3T3 M2XlcGtqdmG|ZTDBd5NigQ>? MVWxJIg> M1jKUGlvcGmkaYTpc44hd2ZiaIXtZY4hTU2OND3meZNm\CCDTFugR|EyPT[\IH31eIFvfCCneIDy[ZN{\WRiYYPz[ZN{\WRiYYOgdIhwe3Cqbz3BUGshdGW4ZXyge4l1cCCLQ{WwJI9nKDBwNEe4JO69VQ>? MnTwNlQ5OTlzMU[=
NIH-3T3 MY\LbY5ie2ViQYPzZZk> NEPsSIsyKGh? NIjhPVVKdmirYnn0bY9vKG:oIHj1cYFvKEWPTESt[pV{\WRiQVzLJGcyOjB{UjDteZRidnRiZYjwdoV{e2WmIHHzd4V{e2WmIHHzJJBpd3OyaH:tRWxMKGyndnXsJJdqfGhiSVO1NEBw\iBzLkG0PEDPxE1? Mn;2NlQ5OTlzMU[=
NIH-3T3 MljHT4lv[XOnIFHzd4F6 M1rMWVEhcA>? MWjJcohq[mm2aX;uJI9nKGi3bXHuJGVOVDRvZoXz[YQhSUyNIEGxOVFVcW6|IH31eIFvfCCneIDy[ZN{\WRiYYPz[ZN{\WRiYYOgdIhwe3Cqbz3BUGshdGW4ZXyge4l1cCCLQ{WwJI9nKDNwMEO5JO69VQ>? MmrXNlQ5OTlzMU[=
KARPAS299 M4T5NWtqdmG|ZTDBd5NigQ>? MWW5NEBucW5? M4rZRWROW09? MX;Jcohq[mm2aX;uJI9nKE6STT3meZNm\CCDTFugdIhwe3Cqb4L5cIF1cW:wIHX4dJJme3OnZDD3bZRpKEmFNUCgc4YhOC5zMTFOwG0> NFT3eFUzPDlyMEe1NC=>
MKN 45 NIXnb3FMcW6jc3WgRZN{[Xl? MnPONUBp MYnEUXNQ M{PVTGlvcGmkaYTpc44hd2ZiYz3N[ZQheGixc4Doc5J6dGG2aX;uJJdqfGhiSVO1NEBw\iByLkCyJO69VQ>? NHvxepQzPDlyMEe1NC=>
A549 NVyx[WFiS3m2b4TvfIlkKEG|c3H5 NIXYWpg1QCCq NImwTGNFVVOR NUTCVYtTUUN3MDDv[kA1NjB6NDFOwG0> NETpXm4zPDlyMEizNC=>
NCI-H1975 MVrDfZRwfG:6aXOgRZN{[Xl? M3rufVQ5KGh? NEH1cGhFVVOR MXjJR|UxKG:oIEeuOVUyKM7:TR?= NGjPUWIzPDlyMEizNC=>
NCI-H1993 MYXDfZRwfG:6aXOgRZN{[Xl? M1fwZlQ5KGh? MUTEUXNQ MWLJR|UxKG:oIECuNFYyKM7:TR?= NYXPVHNlOjR7MEC4N|A>
NCI-H1993 MYrBdI91d3OrczDBd5NigQ>? NXXWTZVHOSEQvF2= MlfGNlQhcA>? M1r3NWROW09? M{fPd4Rw\XNibn;0JIlv\HWlZTDhdI9xfG:|aYO= MW[yOFkxODh|MB?=
NIH-3T3 MWfDfZRwfG:6aXOgRZN{[Xl? NWHQRlB{PDhiaB?= MoGzSG1UVw>? MXrJR|UxKG:oIECuN|Y1KM7:TR?= M{DnVVI1QTByOEOw
EBC1 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkjyO|IhcA>? Mn7oSG1UVw>? M3jxcWlEPTBib3[gNE4xODZ7IN88US=> M17ieFI1QTByOEOx
KARPAS299 NWmyUpRjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1jo[lczKGh? NH;BPY9FVVOR M2H6eGlEPTBib3[gNE4zKM7:TR?= Ml:5NlQ6ODB6M{G=
NB1 M1LifWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIPrUmZKSzVyPUmxMlk5KG6P NWDLTFUzW0GQR1XS
NCI-SNU-5 MlPYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlnyTWM2OD1zMEWuO|Uhdk1? NYrwS3ZkW0GQR1XS
SR M1PuVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGTkVIJKSzVyPUGyOk4{OSCwTR?= NVXKfpJoW0GQR1XS
SF539 NFrU[ZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV7n[I1tUUN3ME2yNFQvOjRibl2= NELWcZFUSU6JRWK=
SU-DHL-1 M{TBdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHnQNYpKSzVyPUOzOk45OiCwTR?= NXfLdpV4W0GQR1XS
SCC-3 M1j5bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn3FTWM2OD1|NU[uO|Yhdk1? NX:yXJM3W0GQR1XS
DEL MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYfGcZIyUUN3ME2zOlkvQSCwTR?= M1HKZ3NCVkeHUh?=
CTV-1 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4fueGlEPTB;NUm2MlQ5KG6P NEjGPFJUSU6JRWK=
EM-2 NW\1OpZkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnnZTWM2OD14MEGuN|Qhdk1? Mn;6V2FPT0WU
MHH-CALL-2 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmroTWM2OD14OEKuOVchdk1? M1\xSnNCVkeHUh?=
KM12 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4X4S2lEPTB;N{C2Mlkhdk1? M3[3SXNCVkeHUh?=
KINGS-1 NELXfXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF[4fGFKSzVyPUe0PU44PSCwTR?= MkO2V2FPT0WU
MEG-01 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIKyWYZKSzVyPUi1O{43PiCwTR?= M2rVbnNCVkeHUh?=
BV-173 NEPuS|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1G0eGlEPTB;MT6wOVk6PyEQvF2= MlnUV2FPT0WU
LAMA-84 NU\kdm9sT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlPNTWM2OD1zLkO4NlgzKM7:TR?= NHXqNZlUSU6JRWK=
KARPAS-299 NEHWU|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW\M[|lqUUN3ME2xMlQxQDZzIN88US=> Mn7LV2FPT0WU
K-562 M{HDZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXTGV5ZZUUN3ME2xMlczOjZ7IN88US=> MX;TRW5ITVJ?
SK-LMS-1 NV7nU2ozT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2npeGlEPTB;MT63Olg3PyEQvF2= NWDzTJVbW0GQR1XS
MOLT-16 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{PDVmlEPTB;MT65OVU4PSEQvF2= MWTTRW5ITVJ?
CMK NYXKRW4zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoWwTWM2OD1zLkm2NVU6KM7:TR?= MWrTRW5ITVJ?
ST486 NVq0bHNqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn25TWM2OD1{LkSzNFc{KM7:TR?= MoLNV2FPT0WU
CI-1 NH[yNVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmHiTWM2OD1{LkS5OlU6KM7:TR?= M2HLOHNCVkeHUh?=
KP-N-RT-BM-1 M1jKRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVjLV|hQUUN3ME2yMlcxOTJ{IN88US=> MVLTRW5ITVJ?
ALL-PO M1[4NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlXNTWM2OD1|LkG4NlA4KM7:TR?= M3nPVXNCVkeHUh?=
KS-1 Mn3LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUPiSI9bUUN3ME2zMlIyOjJ3IN88US=> MXPTRW5ITVJ?
Becker NEnp[pBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkTxTWM2OD12LkKzPVMh|ryP NViySY9[W0GQR1XS
GDM-1 M{nFeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFrYTHRKSzVyPUSuNlQ3OTdizszN M4jPS3NCVkeHUh?=
BC-1 NVrU[G9PT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{\HPGlEPTB;ND60PVI4PyEQvF2= NGWyVnZUSU6JRWK=
NB14 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYjQclVsUUN3ME20Mlg{PTJ2IN88US=> NHfxcWJUSU6JRWK=
NOS-1 NX:yc3d{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIm4RpJKSzVyPUWuN|M5PzRizszN NUHOZYxGW0GQR1XS
MZ1-PC NEHXXGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{fjPWlEPTB;NT64NlE2OSEQvF2= NWTXfYpVW0GQR1XS
A498 NHjKZ29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{jCcGlEPTB;Nj6wPFQ4OyEQvF2= MlPkV2FPT0WU
EW-16 NXjrZoJST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\UWWZKSzVyPU[uN|c4PzNizszN MUXTRW5ITVJ?
NALM-6 M4C3TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUTwV3hHUUN3ME22MlY5Ozh5IN88US=> M{e3cHNCVkeHUh?=
EB-3 NGHEOYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVvQT3k2UUN3ME23MlA4OjN|IN88US=> NVHhU214W0GQR1XS
697 M3vnNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn;VTWM2OD17LkK0N|I6KM7:TR?= NHzxO3NUSU6JRWK=
Ramos-2G6-4C10 M4fxS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml7YTWM2OD17LkW5PFQzKM7:TR?= MXzTRW5ITVJ?
KNS-81-FD NF;uNoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{fjOmlEPTB;OT62PVY2OyEQvF2= NGLsSFdUSU6JRWK=
HUTU-80 Ml3HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX\JR|UxRTlwN{S2OFIh|ryP MnnvV2FPT0WU
LS-411N NYDMNXJpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXTHeXppUUN3ME2xNE4xPTZ5IN88US=> M1nH[nNCVkeHUh?=
RPMI-8402 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWLJR|UxRTFyLkGxOkDPxE1? MVHTRW5ITVJ?
KU812 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRTFyLkK5PVEh|ryP Ml\EV2FPT0WU
EW-1 NVzPOHpRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXTJR|UxRTFyLkS0NlUh|ryP MnLPV2FPT0WU
HC-1 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTFyLkS4OFQh|ryP MoG1V2FPT0WU
NB69 M1;1R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHPRTVFKSzVyPUGwMlUxPDNizszN NFrpbpZUSU6JRWK=
MFH-ino M1nrVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH3De2FKSzVyPUGwMlg{ODNizszN NIj1O|BUSU6JRWK=
CCRF-CEM NHr5Z4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1rxXmlEPTB;MUGuOVk4KM7:TR?= NHfwfXJUSU6JRWK=
SK-N-DZ NYTUW2JoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXr2SWZpUUN3ME2xNk4xPDN4IN88US=> MU\TRW5ITVJ?
NCI-H720 Mli4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{ftc2lEPTB;MUKuNVcxPSEQvF2= NFf1bYxUSU6JRWK=
HCC1187 NHjkOFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4DibmlEPTB;MUKuNlA1OSEQvF2= NF;JO4hUSU6JRWK=
IST-SL2 Mmj4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MorQTWM2OD1zMj60PFczKM7:TR?= NWrhOZVQW0GQR1XS
KE-37 MorzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2HOUGlEPTB;MUKuO|k3PiEQvF2= NVjvdplkW0GQR1XS
HCC1599 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlzUTWM2OD1zMj65NFY6KM7:TR?= M2TkT3NCVkeHUh?=
A4-Fuk NEPNRVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3npW2lEPTB;MUKuPVU5PiEQvF2= MXvTRW5ITVJ?
NKM-1 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3rPUGlEPTB;MUOuNlkzPSEQvF2= MoO5V2FPT0WU
BE-13 NHz0NJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mle2TWM2OD1zMz63PVg6KM7:TR?= NIrZSpBUSU6JRWK=
MV-4-11 NVvLS5JTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmD6TWM2OD1zND6wN|I1KM7:TR?= NXL0dZpFW0GQR1XS
OPM-2 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYTJR|UxRTF2LkSwPFUh|ryP MWfTRW5ITVJ?
KARPAS-422 M3fnPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoDqTWM2OD1zND61NVI3KM7:TR?= NIXtdYJUSU6JRWK=
RPMI-8226 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYLMWJZFUUN3ME2xOE45QTF3IN88US=> M3:4RXNCVkeHUh?=
KARPAS-45 M2DHNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXPJR|UxRTF3Lke3NVYh|ryP NF7KSHZUSU6JRWK=
SK-PN-DW MkPTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXnRWWlpUUN3ME2xOU45PjNzIN88US=> MV3TRW5ITVJ?
LC-2 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHu1VVBKSzVyPUG2MlE2ODZizszN M4TYOXNCVkeHUh?=
NCI-H1648 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUPacZh1UUN3ME2xOk4zPTRizszN MWLTRW5ITVJ?
RL95-2 NHPr[GlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWXJR|UxRTF4LkO5O|gh|ryP NVjxSms{W0GQR1XS
KNS-42 NEj4WGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1S1bGlEPTB;MU[uO|I4PCEQvF2= NUfCTXVmW0GQR1XS
RPMI-6666 MmXXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUHJR|UxRTF4LkmyNVEh|ryP M1\q[HNCVkeHUh?=
SIG-M5 M1:3WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXfJR|UxRTF5LkG5NFMh|ryP M{G1OnNCVkeHUh?=
VA-ES-BJ NXXXd3NtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkPVTWM2OD1zNz63OFUyKM7:TR?= NUXRR2tuW0GQR1XS
MONO-MAC-6 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2DMZWlEPTB;MUeuPVMyOiEQvF2= NGmyZZdUSU6JRWK=
LAN-6 NU\SZpBiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX\JR|UxRTF6Lke1OVch|ryP NUK4RYtQW0GQR1XS
A388 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mlf2TWM2OD1zOT6zNFU6KM7:TR?= NIjSNJhUSU6JRWK=
SK-NEP-1 NFnBbXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3;RR2lEPTB;MkCuNlE{OiEQvF2= M4TETnNCVkeHUh?=
TE-10 NXvEbWhkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoroTWM2OD1{MD61NlIyKM7:TR?= MXHTRW5ITVJ?
HL-60 M2rRNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWXNZmR1UUN3ME2yNE46ODl7IN88US=> M3[wWXNCVkeHUh?=
MC116 NXrYV5hrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRTJzLkeyNlEh|ryP MnezV2FPT0WU
SW962 NF;zb4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmPPTWM2OD1{MT63PVE2KM7:TR?= MnW1V2FPT0WU
NOMO-1 MnjDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYT4VFJNUUN3ME2yNk43PTZ2IN88US=> MYnTRW5ITVJ?
CTB-1 NUHwVI1pT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUnJR|UxRTJ{Lki2O|Eh|ryP NFPwNHdUSU6JRWK=
MRK-nu-1 Ml3ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnrrTWM2OD1{Mj65NFc1KM7:TR?= M1eydnNCVkeHUh?=
GR-ST NXXZXHc4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVXJR|UxRTJ|Lke2JO69VQ>? M1nuU3NCVkeHUh?=
HH NHmxXlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml\wTWM2OD1{ND6wNFMh|ryP M2W3U3NCVkeHUh?=
NCI-H1963 MonPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVLoOIh{UUN3ME2yOE4xPzh{IN88US=> M1zxcXNCVkeHUh?=
QIMR-WIL NX7oOZFVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUfObGpRUUN3ME2yOE45Pzd{IN88US=> M2nCVnNCVkeHUh?=
CGTH-W-1 NUHrfmtGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnHITWM2OD1{NT6wO|I{KM7:TR?= MmLhV2FPT0WU
LP-1 NUmyUHhqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlewTWM2OD1{NT62OVUyKM7:TR?= MXzTRW5ITVJ?
NCI-H748 NGfKO4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml3QTWM2OD1{Nj61NVM4KM7:TR?= MVzTRW5ITVJ?
PF-382 NULDXnhxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWnm[Gh[UUN3ME2yO{4zOjJ|IN88US=> M1rqdHNCVkeHUh?=
ATN-1 MlHJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWDJR|UxRTJ5LkO3N|Ih|ryP MkLJV2FPT0WU
L-540 MkHxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnTOTWM2OD1{Nz62OFU6KM7:TR?= MVXTRW5ITVJ?
LXF-289 NVu3SJZ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoTGTWM2OD1{Nz63OVE6KM7:TR?= NFLscFhUSU6JRWK=
LS-513 NUnoSIhsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV\3SohOUUN3ME2yPE4yQDB5IN88US=> MmKxV2FPT0WU
NCI-H1581 M3TJVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTNyLkO5O|Yh|ryP M2DHcnNCVkeHUh?=
ES6 M173Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYC4TZpHUUN3ME2zNE43QDl7IN88US=> NFHDZ4ZUSU6JRWK=
SW982 MlHLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYrJR|UxRTNyLki1OlYh|ryP M13HSnNCVkeHUh?=
DOHH-2 M1Kyfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV3JR|UxRTNzLkW4PVMh|ryP MnOyV2FPT0WU
DB MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHLMTI5KSzVyPUOzMlk1OzFizszN Mnu4V2FPT0WU
MPP-89 NETmWpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYfJR|UxRTN2LkG3OVYh|ryP MX3TRW5ITVJ?
LB831-BLC NHT0WJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2Phd2lEPTB;M{SuOVE5PCEQvF2= NX3vRpVLW0GQR1XS
NB5 Mn;pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3Tp[mlEPTB;M{SuPFU{PSEQvF2= MVHTRW5ITVJ?
GB-1 NXXWcG5PT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVPwNXg4UUN3ME2zOU4xPDZ7IN88US=> NWjxVJZlW0GQR1XS
TE-15 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWfJR|UxRTN3LkKyN|gh|ryP Mof5V2FPT0WU
LC4-1 NHnpUmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEKwV2xKSzVyPUO1MlM5PDdizszN NWfvZWt7W0GQR1XS
NCI-H747 NEfRdnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmTITWM2OD1|Nj6xN|Y6KM7:TR?= MkfNV2FPT0WU
NTERA-S-cl-D1 M4fnR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnfzTWM2OD1|OD63N|Q4KM7:TR?= MWLTRW5ITVJ?
SK-MM-2 NH7BZnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWfJR|UxRTRyLkGxOFYh|ryP MVfTRW5ITVJ?
TGW MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmDuTWM2OD12MT6wOVY{KM7:TR?= NV7x[INnW0GQR1XS
ONS-76 NInxemZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYnSU2M{UUN3ME20Nk41QDh|IN88US=> NVPjco9LW0GQR1XS
CPC-N Ml7ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXJR|UxRTR{Lkm5O|Eh|ryP M1K0TXNCVkeHUh?=
ES4 NG\NUXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MonaTWM2OD12ND60NVU{KM7:TR?= MkfPV2FPT0WU
Daudi MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlvNTWM2OD12NT6wPFI4KM7:TR?= NVTySItsW0GQR1XS
MOLT-4 NGTufnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnWxTWM2OD12NT6wPFU{KM7:TR?= MX7TRW5ITVJ?
HT-144 M2DhXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEXTUJFKSzVyPUS2MlczPiEQvF2= MnvPV2FPT0WU
SW872 NY\oSHR4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW\jUVY1UUN3ME20PE4yQTN|IN88US=> NHvoWoFUSU6JRWK=
D-283MED MnfLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW\ZdJpmUUN3ME20PE4{PTR{IN88US=> MWDTRW5ITVJ?
NCI-H2126 NUXOcHlTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTR6Lki0O|Yh|ryP MnXhV2FPT0WU
NCI-SNU-16 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEf1fJhKSzVyPUS5MlIyPDNizszN MnrSV2FPT0WU
CESS M362e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MljlTWM2OD12OT61NFg5KM7:TR?= NVXDVVBbW0GQR1XS
A101D MnTUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYruXpJbUUN3ME20PU46PzN4IN88US=> M1HJbnNCVkeHUh?=

... Click to View More Cell Line Experimental Data

In vivo In the GTL-16 model, PF-2341066 reveals the ability to cause marked regression of large established tumors (>600 mm3) in both the 50 mg/kg/day and 75 mg/kg/day treatment cohorts, with a 60% decrease in mean tumor volume over the 43-day administration schedule. In an another study, PF-2341066 displays the ability to completely inhibits GTL-16 tumor growth for >3 months, with only 1 of 12 mice exhibiting a significant increase in tumor growth over the 3-month treatment schedule at 50 mg/kg/day. In the NCI-H441 NSCLC model, a 43% decrease in mean tumor volume is observed at 50 mg/kg/day during the 38-day PF-2341066 administration cycle. In the Caki-1 RCC model, a 53% decrease in mean tumor volume is observed to be associated with decreased volume of each tumor by at least 30% at 50 mg/kg/day during the 33-day PF-2341066 administration cycle. PF-2341066 also reveals near-complete prevention of the growth of established tumors at 50 mg/kg/day in the U87MG glioblastoma or PC-3 prostate carcinoma xenograft models, with 97% or 84% inhibition on the final study day, respectively. In contrast, PF-2341066 p.o. given at 50 mg/kg/day does not significantly inhibit tumor growth in the MDA-MB-231 breast carcinoma model, or the DLD-1 colon carcinoma model. A significant dose-dependent reduction of CD31–positive endothelial cells is observed at 12.5 mg/kg/day, 25 mg/kg/day, and 50 mg/kg/day in GTL-16 tumors, indicating that inhibition of MVD shows a dose-dependent correlation to antitumor efficacy. PF-2341066 displays a significant dose-dependent reduction of human VEGFA and IL-8 plasma levels in both the GTL-16 and U87MG models. Marked inhibition of phosphorylated c-Met, Akt, Erk, PLCλ1, and STAT5 levels is observed in GTL-16 tumors following p.o. administration of PF-2341066.[1] P.o. administration of PF-2341066 to severe combined immunodeficient-Beige mice bearing Karpas299 ALCL tumor xenografts leads to dose-dependent antitumor efficacy with complete regression of all tumors at the 100 mg/kg/d dose within 15 days of initial compound administration. In addition, inhibition of key NPM-ALK signaling mediators, including phospholipase C-gamma, signal transducers and activators of transcription 3, extracellular signal-regulated kinases, and Akt by PF-2341066 are observed at concentrations or dose levels, which correlated with inhibition of NPM-ALK phosphorylation and function.[2] PF-2341066 prevents osteosarcoma behavior associated with primary tumor growth (eg, proliferation and survival) as well as metastasis (eg, invasion and clonogenicity). In nude mice treated with PF-2341066 via oral gavage, the growth and associated osteolysis and extracortical bone matrix formation of osteosarcoma xenografts are prevented by PF-2341066.[3] Treatment of c-MET-amplified GTL-16 xenografts with 50 mg/kg PF-2341066 elicits tumor regression that is associated with a slow reduction in 18F-FDG uptake and decreases expression of the glucose transporter 1, GLUT-1.[4]

Protocol

Kinase Assay:

[1]

+ Expand

Cellular kinase phosphorylation ELISA assays:

Cells are seeded in 96-well plates in media supplemented with 10% fetal bovine serum (FBS) and transferred to serum-free media [with 0.04% bovine serum albumin (BSA)] after 24 h. In experiments investigating ligand-dependent RTK phosphorylation, corresponding growth factors are added for up to 20 min. After incubation of cells with PF-2341066 for 1 h and/or appropriate ligands for the designated times, cells are washed once with HBSS supplemented with 1 mM Na3VO4, and protein lysates are generated from cells. Subsequently, phosphorylation of selected protein kinases is assessed by a sandwich ELISA method using specific capture antibodies used to coat 96-well plates and a detection antibody specific for phosphorylated tyrosine residues. Antibody-coated plates are (a) incubated in the presence of protein lysates at 4°C overnight; (b) washed seven times in 1% Tween 20 in PBS; (c) incubated in a horseradish peroxidase–conjugated anti–total-phosphotyrosine (PY-20) antibody (1:500) for 30 min; (d) washed seven times again; (e) incubated in 3,3′,5,5′-tetramethyl benzidine peroxidase substrate to initiate a colorimetric reaction that is stopped by adding 0.09 N H2SO4; and (f) measured for absorbance in 450 nm using a spectrophotometer.
Cell Research:

[1]

+ Expand
  • Cell lines: GTL-16 gastric carcinoma cells and T47D breast carcinoma cells
  • Concentrations: 0-256 nM
  • Incubation Time: 1 hour
  • Method:

    Cells including GTL-16 gastric carcinoma cells and T47D breast carcinoma cells are seeded in 96-well plates in media supplemented with 10% fetal bovine serum (FBS) and transferred to serum-free media [with 0.04% bovine serum albumin (BSA)] after 24 hours. In experiments investigating ligand-dependent RTK phosphorylation, corresponding growth factors are added for up to 20 minutes. After incubation of cells with PF-2341066 for 1 hour and/or appropriate ligands for the designated times, cells are washed once with HBSS supplemented with 1 mM Na3VO4, and protein lysates are generated from cells. Subsequently, phosphorylation of selected protein kinases is assessed by a sandwich ELISA method using specific capture antibodies used to coat 96-well plates and a detection antibody specific for phosphorylated tyrosine residues. Antibody-coated plates are (a) incubated in the presence of protein lysates at 4 °C overnight; (b) washed seven times in 1% Tween 20 in PBS; (c) incubated in a horseradish peroxidase–conjugated anti–total-phosphotyrosine (PY-20) antibody (1:500) for 30 min; (d) washed seven times again; (e) incubated in 3,3,5,5-tetramethyl benzidine peroxidase substrate to initiate a colorimetric reaction that is stopped by adding 0.09 N H2SO4; and (f) measured for absorbance in 450 nm using a spectrophotometer.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: Female or male nu/nu mice bearing NCI-H441,or DLD-1, or MDA-MB-231
  • Formulation: --
  • Dosages: 12.5 mg/kg/day, 25 mg/kg/day, and 50 mg/kg/day
  • Administration: Administered via p.o.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 9 mg/mL (19.98 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents individually and in order:
5% DMSO+30% PEG 300+dd H2O
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 450.34
Formula

C21H22Cl2FN5O

CAS No. 877399-52-5
Storage powder
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03052608 Not yet recruiting Carcinoma, Non-Small-Cell Lung Pfizer March 2017 Phase 3
NCT02838420 Recruiting Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer Hoffmann-La Roche August 2016 Phase 3
NCT02836847 Recruiting Cholangiocarcinoma of the Extrahepatic Bile Duct|Gallbladder Cancer Shanghai Jiao Tong University School of Medicine|Xinhua Hospital, Shanghai Jiao Tong University School of Medicine|Ruijin Hospital|RenJi Hospital|Eastern Hepatobiliary Surgery Hospital|Huashan Hospital July 2016 Phase 2
NCT02946359 Recruiting Lung Adenocarcinoma Metastatic Chinese PLA General Hospital July 2016 Phase 2
NCT02679170 Recruiting Non-Small Cell Lung Cancer Pfizer June 2016 --
NCT02767804 Recruiting Non-small Cell Lung Cancer Xcovery Holding Company, LLC June 2016 Phase 3

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Could you tell me whether this product represents the pure R-form of crizotinib, or is the the racemic Crizotinib, so a mixture of the S- and the R-form?

  • Answer:

    Our S1068 Crizotinib is R enantiomer(except batch 05 and 06, they are racemate), and S7505 is S enantiomer.

Related Antibodies

c-Met Signaling Pathway Map

c-Met Inhibitors with Unique Features

Related c-Met Products

Tags: buy Crizotinib (PF-02341066) | Crizotinib (PF-02341066) supplier | purchase Crizotinib (PF-02341066) | Crizotinib (PF-02341066) cost | Crizotinib (PF-02341066) manufacturer | order Crizotinib (PF-02341066) | Crizotinib (PF-02341066) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID